MarketVIEW Travel Vaccines  ·  February 2018 edition, updated August 2026

Dengue Traveler
Vaccines Forecast

Dengue is the second most common specific cause of fever diagnosed in ill returned travelers worldwide, after malaria alone, and the single most common cause among travelers returning from Southeast Asia and South Central Asia. 2024 was the worst year for dengue on record, with more than 14 million cases reported worldwide, and elevated transmission has persisted into 2025/26. Yet the current vaccine landscape still is not built for the traveler segment: Sanofi is discontinuing Dengvaxia in 2026, and Takeda's newer Qdenga (TAK-003) remains guided, in practice, toward travelers with confirmed prior dengue infection rather than the first-time exposure typical of most Western visitors. This is a comprehensive, traveler-specific commercial assessment of that opportunity, drawing on VacZine Analytics' long standing, independent authority in travel disease vaccine markets.

14.1M Cases Worldwide in 2024 - A Record Year Qdenga Authorized in 40+ Countries 85 Countries With Ongoing Transmission Dengvaxia Discontinuing in 2026
Product catalogue
VAMV025a
February 2018 edition, updated August 2026

Format
Executive presentation + Excel model
Coverage
85 countries, from major Western origins
Traveler types
Vacation, VFR & business
Forecast horizon
To 2030
Approach
Value/volume by type & serostatus
Base edition
Feb 2018, updated Aug 2026
Availability
Syndicated / bespoke
2nd
Most common cause of fever in
ill returned travelers, after malaria
14.1M
Dengue cases reported worldwide
in 2024, a record year
85
Countries with ongoing transmission
covered in this traveler model
2030
Forecast horizon for traveler-
segment vaccine demand
Disease background

A leading cause of travel-related fever, still without a traveler-suited vaccine

This review sets out dengue's role in traveler-importation dynamics, a historical European case study, and the record case surges of recent years, before turning to how well (or poorly) today's licensed and pipeline vaccines actually fit the traveler segment.

Traveler epidemiology & 2025/26 update

Pathogen overview - Dengue virus (DENV-1 to DENV-4) in the traveler segment

Dengue Fever (DF) is a mosquito-borne disease, transmitted by Aedes mosquitoes and caused by single-strand RNA viruses of the family Flaviviridae. Among ill returned travelers, dengue is the second most common specific cause of febrile illness worldwide, after malaria alone, and the single most common cause of fever among travelers returning from Southeast Asia and South Central Asia, a pattern that has held consistently across successive multi-year surveillance periods. The disease poses a risk not only to the individual traveler but also to public health more broadly: returning viraemic travelers can seed onward transmission wherever a competent Aedes vector population is already established.

Madeira, Portugal (2012-13) remains the clearest European case study of that importation pathway. Local Aedes aegypti populations, combined with viraemic arrivals, produced an autochthonous outbreak of roughly 2,000 cases, the largest of its kind recorded in the EU. With Aedes albopictus now established across much of southern and even central Europe, and further northward range creep documented in recent years, the underlying risk pathway that produced Madeira's outbreak has, if anything, widened rather than receded.

Recent case-surge data reinforce that picture at global scale. 2024 was the worst year for dengue on record: more than 14 million cases were reported worldwide across upward of 100 countries, more than double the total recorded in 2023, itself a previous record year. The World Health Organization and the Pan American Health Organization attribute the surge to a combination of urbanisation, El Nino-linked climate variability and rising temperatures, which have already increased the transmission potential of Aedes aegypti by an estimated 42.7% since the 1950s, and continuing Aedes range expansion into previously unaffected latitudes. 2025 brought a substantial pullback in the Americas, down around two-thirds from 2024's peak, but global case counts still exceeded 5 million across some 106 countries and territories through early December 2025, with all four dengue serotypes co-circulating simultaneously, a configuration that keeps outbreak potential, and traveler risk from major Western source markets, elevated.

2026 2nd most common travel fever cause after malaria  |  14.1M cases worldwide in 2024  |  Madeira 2012-13: ~2,000 EU cases  |  85 countries with ongoing transmission modelled
Product & competitor landscape

A vaccine landscape still built around prior exposure, not first-time travelers

Sanofi's Dengvaxia is exiting the market just as Takeda's Qdenga (TAK-003, previously known during earlier development as DenVax) expands internationally, but neither vaccine, nor the field's remaining pipeline candidates, is straightforwardly suited to the first-time-exposure profile typical of most Western travelers.

  • Sanofi PasteurDiscontinuing, Q3 2026
    Dengvaxia (CYD-TDV) 3-dose, 0/6/12-month schedule
    Sanofi is discontinuing global production of Dengvaxia due to low demand; existing lots expire in August 2026 and will not be replaced. The vaccine was never well suited to travelers, given its long three-dose schedule and, since 2018, a label restriction to individuals with laboratory-confirmed prior dengue infection, a screening hurdle most travelers cannot clear before departure.
  • TakedaApproved, 40+ countries
    Qdenga (TAK-003) Live-attenuated, 2-dose, 3 months apart
    EU approved since 2022 and now authorized across more than 40 countries in Europe, Latin America and Asia, including the UK, Brazil, Argentina, Indonesia, Thailand and India. In the US, Takeda voluntarily withdrew its FDA application in 2023 after the agency requested additional data beyond the pivotal TIDES trial; no US approval has followed, and resubmission timing remains unclear. Qdenga's label in most approved markets does not mandate pre-vaccination screening, a genuine advantage over Dengvaxia's screen-and-vaccinate approach, but travel-medicine bodies have so far applied their own caution: the UK's JCVI/NaTHNaC guidance recommends Qdenga for travelers only where a previous dengue infection is confirmed, stating that current trial data remain insufficient to recommend it to seronegative travellers. In September 2026, Takeda entered an exclusive agreement with Dr Reddy's Laboratories to promote and distribute Qdenga across India's private paediatric and adult market, with availability expected from H1 2027 subject to further regulatory steps, a further sign of Qdenga's continuing international commercial rollout in a major VFR-travel source and destination market.
  • NIH / Instituto ButantanApproved Brazil, suspended Jun 2026
    TetraVax-DV (TV003/TV005), marketed in Brazil as Butantan-DV
    A single-dose, live-attenuated tetravalent candidate licensed from the US NIH. Brazil's health authorities approved Butantan-DV in December 2025 for individuals aged 12-59, but the Brazilian Ministry of Health temporarily suspended its use in June 2026 pending an investigation into adverse event reports, alongside continued Bangladesh Phase II follow-up of TV005. This remains the field's most credible longer-term rival to Qdenga, though it is not yet positioned or labelled specifically for the traveler segment, and the suspension is a reminder of the safety-data bar any new entrant must clear first.
  • Walter Reed Army Institute of ResearchDiscontinued
    TDENV-PIV (purified inactivated vaccine)
    This tetravalent purified-inactivated candidate progressed through early-phase testing with GSK adjuvant systems but has since been discontinued and is no longer an active traveler-segment contender.
  • UK NaTHNaC/JCVI, US CDC/ACIP, ECDC, Australia ATAGIActive guidance tracking
    Travel-medicine body recommendations
    National travel-health authorities continue to update country-specific dengue vaccination guidance season by season as Qdenga's international approvals expand and Dengvaxia is phased out, an evolving picture this analysis tracks closely. In a June 2026 review of its Country Information pages, the UK's NaTHNaC/UKHSA extended a dengue vaccine recommendation (for eligible travellers) to most destinations with a known dengue risk, while confirming that around eight lower-risk destinations, including the USA, Spain, Italy, France and Australia, still carry no vaccine recommendation and remain covered only under general "other risks" advice; the underlying Qdenga eligibility criteria for UK travellers were not changed by this update. Australia became Qdenga's latest travel-relevant market in 2026: following TGA approval in April, the Australian Technical Advisory Group on Immunisation (ATAGI) issued dedicated travel guidance in September recommending a risk-based approach that reaches beyond confirmed prior infection, covering travellers with a previous dengue history, long-term or repeat travellers to endemic destinations and, following individual risk-benefit assessment, some shorter trips, a notably broader traveler remit than the UK's confirmed-prior-infection-only stance. Qdenga became available to order through Australian GP/travel clinics from 1 October 2026, via private prescription outside the National Immunisation Program.
Traveler segment reality check
Still screen-gated

Dengvaxia's exit and Qdenga's international rollout have not, in practice, opened the traveler segment as widely as the headline regulatory picture suggests. The world's two licensed dengue vaccines both concentrate protection on individuals with confirmed prior dengue infection, one by explicit label restriction, the other by cautious travel-medicine guidance layered on top of a more permissive label. That leaves a genuine, quantifiable gap for a first-time-infection-friendly vaccine among the vacation, VFR and business travelers who make up the bulk of Western dengue exposure. The VacZine Analytics model sizes both that opportunity and the addressable population actually captured under current guidance, by traveler type and serostatus, to 2030.

Scope of analysis

Six analytical layers - one traveler-segment picture

This is a genuinely traveler-specific report, spanning disease burden, competitor and guidance tracking, and scenario-based demand forecasting from major Western points of origin to 85 countries with ongoing transmission, to 2030.

85-country traveler-origin forecast

Value ($m) and volume (mio doses) demand modelling to 2030, from major Western points of origin to 85 countries with ongoing dengue transmission.

Competitor & traveler-suitability review

Full comparison of Dengvaxia, Qdenga, TetraVax-DV and TDENV-PIV against the specific needs of the traveler segment.

Traveler-type & serostatus segmentation

Vacation, visiting friends/family (VFR) and business/other traveler segments, each split by first-time and repeat/experienced serostatus.

Disease burden & epidemiology

Traveler-importation dynamics, the Madeira 2012-13 case study, and updated global burden data through the 2024 record case surge and 2025/26 season.

Travel-medicine guidance tracking

Country-by-country dengue vaccination recommendation status from UK NaTHNaC/JCVI, US CDC/ACIP and ECDC, tracked as guidance evolves.

Early decision-making support

Designed as an ideal tool to aid early-stage decision making in dengue traveler-vaccine positioning, investment and market entry planning.

Sample analysis

A glimpse of the commercial model

The table below shows a partial view of the traveler-type and geography framework. Full volume/value outputs, serostatus splits and country-level data are in the licensed model.

Traveler typeGeography of originDestination regionVaccine suitabilityRevenue scenario
Vacation travelersUS, UK & Western EuropeSoutheast AsiaQdenga (confirmed prior infection only)Modelled
Visiting friends/family (VFR)US, Canada & Western EuropeSouth Central Asia & CaribbeanQdenga (confirmed prior infection only)Modelled
Business & other travelMajor Western origin marketsLatin America & Sub-Saharan AfricaNo vaccine currently recommended (seronegative)Modelled
█████████████████████████$██m (base)
█████████████████████████$██m (upside)
Total addressable - baseAll originsAll destinationsAll scenarios$███m
Full model in the licensed workbook
85 countries · to 2030 · by traveler type & serostatus
Register interest →
Deliverables

What you receive

A comprehensive intelligence package combining a detailed executive presentation and a fully interactive forecast model, built for organisations evaluating the dengue traveler vaccine opportunity.

  • Executive presentation (~80 slides) - disease background, traveler-importation epidemiology, the Madeira 2012-13 case study, and full competitor and guidance landscape review
  • MS-Excel workbooks (~90 worksheets) - value ($m) and volume (mio doses) predictions to 2030 by traveler type and serostatus
  • 85-country traveler-origin demand model - from major Western points of origin to all countries with ongoing dengue transmission
  • Competitor intelligence - Dengvaxia's confirmed 2026 discontinuation, Qdenga's international rollout, and TetraVax-DV's Phase III progress
  • Travel-medicine guidance tracker - country-by-country recommendation status from UK NaTHNaC/JCVI, US CDC/ACIP and ECDC, tracked as it evolves
  • Updated epidemiology module - the record 2024 global case surge and continued elevated transmission through the 2025/26 season
Target audience

Built for organisations evaluating the dengue traveler vaccine opportunity

Most valuable to teams assessing the traveler-specific dengue vaccine market against their own pipeline, travel-health service line or investment thesis, now that Dengvaxia is exiting and Qdenga's international footprint is expanding.

Vaccine developers

Target product profile and positioning guidance for a genuinely first-time-infection-friendly traveler vaccine candidate.

Travel medicine & occupational health providers

Independent benchmarking of vaccine suitability across traveler types, to support clinic-level advice as guidance evolves.

Investors & analysts

Independent read on Qdenga's international commercial trajectory and the commercial gap left by Dengvaxia's exit.

Corporate travel & duty-of-care programmes

Business-traveler risk assessment and vaccination-policy planning across high-transmission destination regions.

Public health & travel-health policy bodies

Supporting evidence base for country-level travel vaccination guidance development as the competitive landscape shifts.

Researchers & academia

Comprehensive traveler-importation epidemiology and serostatus segmentation for grant and translational planning.

About this analysis · VAMV025a

VacZine Analytics has a long standing expertise in travel diseases, tracking the dengue traveler vaccine opportunity since our original February 2018 edition, well before Qdenga's international approval and long before Sanofi confirmed Dengvaxia's discontinuation. This is a genuinely traveler-specific analysis, distinct from broader endemic-market dengue coverage, and it has been well received by clients for the depth of its traveler-type and serostatus segmentation. Few groups have followed this specific segment as closely, and that recognised, independent expertise underpins everything in the analysis.

This February 2018 edition has been updated, August 2026, to incorporate the record 2024 global case surge, Qdenga's expanding international approvals and current travel-medicine guidance, and Dengvaxia's confirmed 2026 discontinuation. The full syndicated MarketVIEW edition proceeds subject to sufficient client buy-in; where a faster or more tailored answer is required, VacZine Analytics can also be commissioned to deliver bespoke, ad-hoc analysis on this market.

MarketVIEW · VAMV025a · Syndicated & bespoke

Syndicate the refresh - or commission the answer you need

Register your interest to help shape and secure a full syndicated MarketVIEW refresh, which proceeds subject to sufficient client buy-in. Single-licence and multi-user options follow on publication. Need something faster or more specific? VacZine Analytics can be commissioned for bespoke, ad-hoc dengue traveler-vaccine analysis, a briefing call is included on request.